Pages that link to "Q36470715"
Jump to navigation
Jump to search
The following pages link to Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses (Q36470715):
Displaying 14 items.
- Prospects for the therapeutic use of anticancer vaccines (Q33588526) (← links)
- DNA and RNA-based vaccines: principles, progress and prospects (Q33783789) (← links)
- Reverse genetics modification of cytomegalovirus antigenicity and immunogenicity by CD8 T-cell epitope deletion and insertion (Q34495529) (← links)
- Assumptions of the tumor 'escape' hypothesis (Q34583258) (← links)
- Stimulation of anti-tumor immunity by photodynamic therapy (Q34697795) (← links)
- Cancer vaccines: progress reveals new complexities (Q34774541) (← links)
- Developing recombinant and synthetic vaccines for the treatment of melanoma. (Q35946196) (← links)
- The new vaccines: building viruses that elicit antitumor immunity. (Q35946203) (← links)
- The next wave of recombinant and synthetic anticancer vaccines (Q36470749) (← links)
- Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer (Q36916492) (← links)
- Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro (Q36924579) (← links)
- Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A. (Q42134929) (← links)
- Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus (Q45765914) (← links)
- Modified Vaccinia Virus Ankara Can Induce Optimal CD8+ T Cell Responses to Directly Primed Antigens Depending on Vaccine Design (Q92376597) (← links)